The Cost of Cures: Drug Price Controls vs. Biopharmaceutical Innovation

Thursday, June 20, 2019 - 2:00 PM to 3:30 PM
Russell Senate Office Building, Room 385
2 Constitution Ave NE
Washington, DC 20002

There is an increasingly intense focus in Washington on reducing the price of drugs to bring down health care costs. President Trump has proposed a plan that would use an international pricing index model for drugs covered under Medicare Part B. There are proposals from both sides of the aisle in Congress as well, including various forms of government-led arbitration and changes to U.S. patent laws. But much of this debate is taking place without systematic consideration of what effect, if any, mandated drug-price reductions would have on biopharmaceutical innovation and U.S. industry competitiveness.

Please join ITIF and the American Action Forum for an expert panel discussion and debate delving into this critical issue.

Follow @ITIFdc and join the discussion on Twitter with the hashtag #ITIFdrugpricing

06/20/2019 14:0006/20/2019 15:30America/New_YorkThe Cost of Cures: Drug Price Controls vs. Biopharmaceutical InnovationMM/DD/YYYY
Robert D. Atkinson
Information Technology and Innovation Foundation
Douglas Holtz-Eakin
American Action Forum
Stephen Ezell
Vice President, Global Innovation Policy
Information Technology and Innovation Foundation
Andrew Spiegel
Executive Director
Global Colon Cancer Association